Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer

Japanese Journal of Cancer Research

Volumn 91, Issue 4, 2000, Pages 416-423

  Koga, Fumitaka ^a,b   Kitahara, Satoshi ^a   Arai, Kyoko ^a   Honda, Mikihiko ^a   Sumi, Shuhei ^a   Yoshida, Ken Ichiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO ROSAI HOSPITAL   (Japan)

Author keywords

Bladder; Chemosensitivity; P21; P53; Transitional cell carcinoma

Indexed keywords

CISPLATIN; PIRARUBICIN; PROTEIN P21; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; EXON; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0034108062     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00961.x     Document Type: Article

References (30)

1. McCaffrey, J. A., Bajorin, D. F., Scher, H. I. and Bosl, G. J. Combined-modality therapy for bladder cancer. Oncology (Huntingt.), 11, 18-26 (1997).
2. Freiha, F., Reese, J. and Torti, F. M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol., 155, 495-500 (1996).
3. Splinter, T. A. W., Scher, H. I., Denis, L., Bukowski, R., Simon, S., Klimberg, I., Soloway, M., Vogelzang, N. J., Tinteren, H., Herr, H. and EORTC-GU Group. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol. 147, 606-608 (1992).
4. Sternberg, C. N., Arena, M. G., Calabresi, F., Carli, P. D., Platania, A., Zeuli, M., Giannarelli, D., Cancrini, A. and Pansadoro, V. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer, 72, 1975-1982 (1993).
5. Arima, K., Tochigi, H., Sugimura, Y. and Kawamura, J. Balloon-occluded arterial infusion as a useful neoadjuvant chemotherapy for bladder cancer. Br. J. Urol., 80, 417-420 (1997).
6. Harris, C. C. Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeulic strategies. J. Natl. Cancer Inst., 88, 1442-1455 (1996).
7. El-Deiry, W., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
8. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
9. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704 (1993).
10. El-Deiry, W., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrel, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174 (1994).
11. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, E. and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391-3395 (1994).
12. Kawasaki, T., Tomita, Y., Bilim, V., Takeda, M., Takahashi, K. and Kumanishi, T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int. J. Cancer, 68, 501-505 (1996).
13. Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B. and Barnett, G. H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogen, 13, 1279-1285 (1996).
14. Blagosklonny, M. V. and El-Deiry, W. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int. J. Cancer, 75, 933-940 (1998).
15. Hawkins, D., Demers, W. and Galloway, D. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
16. Waldman, T., Lengauer, C., Kinzler, K. W. and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713-716 (1996).
17. International Union Against Cancer. "TNM Atlas," 4th Ed. (1997). Springer, Tokyo.
18. Japanese Urological Association and the Japanese Society of Pathology. "General Rule for Clinical and Pathological Studies on Bladder Cancer." 2nd Ed. (1993). Kanehara Co., Tokyo.
19. Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S., Skinner, D. G., Jones, P. A. and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143, 1389-1397 (1993).
20. Watanabe, H., Fukuchi, K., Takagi, Y., Tomoyasu. S., Tsuruoka, N. and Gomi, K. Molecular analysis of the Cipl/Waf1 (p21) gene in diverse types of human tumors. Biochim. Biophys. Acta, 1263, 275-280 (1995).
21. Lacombe, L., Orlow, I., Silver, D., Gerald, W. L., Fair, W. R., Reuter, V. E. and Cordon-Cardo, C. Analysis of p21 WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8, 409-414 (1996).
22. WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90, 1072-1079 (1998).
23. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A. and Skinner, D. G. p53 and treatment of bladder cancer. Nature, 385, 123-124 (1997).
24. Kakehi, Y., Özdemir, E., Habuchi, T., Yamabe, H., Hashimura, T., Katsura, Y. and Yoshida, O. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn. J. Cancer Res., 89, 214-220 (1998).
25. Sengelov, L., Horn, T. and Steven, K. p53 nuclear reactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol., 123, 565-570 (1997).
26. Siu, L. L., Banerjee, D., Khurana, R. J., Pan, X., Pflueger, R., Tannock, I. F. and Moore, M. J. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin. Cancer Res., 4, 559-565 (1998).
27. Dergham, S. T., Dugan, M. C., Joshi, U. S., Chen, Y. C., Du, W., Smith, D. W., Arlauskas, P., Crissman, J. D., Vaitkevicius, V. K. and Sarkar, F. H. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Cancer, 80, 372-381 (1997).
28. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331, 1259-1264 (1994).
29. Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya. T. and Koshiba, K. p53 mutations and prognosis in bladder tumors. J. Urol. J53, 1097-1104 (1995).
30. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C. and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13, 1384-1390 (1995).